Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd C.PHRM

Alternate Symbol(s):  PHRRF

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

GlobeNewswire July 13, 2022

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

GlobeNewswire June 29, 2022

PharmaTher (CSE:PHRM) announces positive results from KETABET study

John Ballem  June 7, 2022

PharmaTher Announces Positive Results from Study of KETABET(TM) for Depression

GlobeNewswire June 7, 2022

PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

GlobeNewswire May 25, 2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

GlobeNewswire May 5, 2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

GlobeNewswire April 25, 2022

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

GlobeNewswire April 12, 2022

PharmaTher announces positive topline results from clinical study of ketamine for Parkinson's Disease

Stockhouse Editorial March 24, 2022

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson's Disease

GlobeNewswire March 23, 2022

Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes

Business Wire March 1, 2022

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

GlobeNewswire February 16, 2022

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

GlobeNewswire February 1, 2022

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

GlobeNewswire January 17, 2022

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

GlobeNewswire January 12, 2022

PharmaTher Announces Publication of Research Data for KETABET(TM)

GlobeNewswire January 4, 2022

PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

GlobeNewswire December 21, 2021

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

GlobeNewswire December 20, 2021

PharmaTher Announces Positive Research Results for LSD Microneedle Patch

GlobeNewswire December 14, 2021

PharmaTher Granted New Japanese Patent for KETABET(TM) (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

GlobeNewswire November 30, 2021